Synapse - Works

Results (115370)

Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study

Meeting Abstract

Brose, M. S.; Westphalen, C. B.; Kehl, K. L.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Treatment modifications and mortality among female patients with subsequent breast cancer: A report from the Childhood Cancer Survivor Study (CCSS)

Meeting Abstract

Turcotte, L. M.; Hasan, H.; Stene, E.; Monick, S. E.; Rader, R.; Sheade, J.; Wolfe, H. R.; Lu, Z.; Spector, L.; McDonald, A. J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)

Meeting Abstract

Li, J.; Chi, P.; Kang, Y. K.; Cao, H.; George, S.; Zhang, J.; Zhang, J.; Hu, K.; Zhang, L. J.; Xu, Y. H.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2- breast cancer (BC)

Meeting Abstract

Juric, D.; Patel, M. R.; Duska, L. R.; Jhaveri, K. L.; Henick, B. S.; Matulonis, U. A.; Munster, P. N.; Birrer, M. J.; Moore, K. N.; Curigliano, G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL)

Meeting Abstract

Freedland, S. J.; Mulhall, J.; Gleave, M.; De Giorgi, U.; Rannikko, A.; Saad, F.; Ramirez-Backhaus, M.; Ivanova, J. I.; Nasr, A. F.; Ganguli, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)

Meeting Abstract

Azad, A.; Musto, C.; Netanel, S.; Zhang, T.; Rathkopf, D. E.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Runcie, K.; Dos Santos, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)

Meeting Abstract

Barlesi, F.; Felip, E.; Popat, S.; Solomon, B. J.; Wolf, J.; Li, B. T.; Wu, Y. L.; Kerr, K.; Akamatsu, H.; Camidge, D. R.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Associations of prior lung diseases on risk of lung cancer in populations with no smoking history: A systematic review and meta-analysis

Meeting Abstract

Swami, N.; Hong, J. H.; Kho, S.; Kang, H.; Lin, L.; Ni, S.; Dee, E. C. C.; Florez, N.; Gomez, S. L.; Cheng, I.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Study of ELU001, a C'Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors

Meeting Abstract

Ma, W. W.; Tolcher, A. W.; Perez, C. A.; Hendrickson, A. E. W.; Orr, D. W.; Murciano-Goroff, Y. R.; Anders, C. K.; Hamilton, E. P.; Swisher, E. M.; Mathews, C. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

Meeting Abstract

Andre, F.; Hamilton, E. P.; Loi, S.; Anders, C. K.; Schmid, P.; Stroyakovskiy, D.; Villanueva, R.; Pedrini, J. L.; Doval, D. C.; Zurawski, B.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save